Effects of Sandostatin LAR® in Acromegaly

Summary

This study aims primarily to determine the effect Insulin-like Growth Factor 1 (IGF-1) normalization into current IGF-I normal ranges with Sandostatin LAR® therapy on biochemical metabolic, cardiovascular and body composition parameters in patients with active acromegaly.

Timeline

Start

2006-10

Primary completion

2013-03

Completion

2014-01

Drugs

Indications